Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rapid Micro Biosystems (RPID) EBIAT (2020 - 2025)

Rapid Micro Biosystems' EBIAT history spans 6 years, with the latest figure at -$12.5 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 29.29% to -$12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.1 million, a 0.5% change, with the full-year FY2025 number at -$47.1 million, changed 0.5% from a year prior.
  • EBIAT hit -$12.5 million in Q4 2025 for Rapid Micro Biosystems, down from -$11.5 million in the prior quarter.
  • Over the last five years, EBIAT for RPID hit a ceiling of -$9.7 million in Q4 2024 and a floor of -$25.0 million in Q3 2021.
  • Historically, EBIAT has averaged -$14.0 million across 5 years, with a median of -$13.2 million in 2022.
  • Biggest five-year swings in EBIAT: plummeted 193.96% in 2021 and later soared 34.61% in 2022.
  • Tracing RPID's EBIAT over 5 years: stood at -$14.6 million in 2021, then decreased by 12.61% to -$16.4 million in 2022, then skyrocketed by 32.07% to -$11.2 million in 2023, then increased by 13.48% to -$9.7 million in 2024, then decreased by 29.29% to -$12.5 million in 2025.
  • Business Quant data shows EBIAT for RPID at -$12.5 million in Q4 2025, -$11.5 million in Q3 2025, and -$11.9 million in Q2 2025.